Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.
Among cancer survivors with diabetes, semaglutide showed lower cardiovascular risk than other GLP-1 drugs over five years.
This target-trial emulation using an electronic-health-record cohort examined semaglutide versus other glp-1 ras and cardiovascular risk in obesity-related cancer survivors. The PubMed abstract reports among 918 matched obesity-related cancer survivors with diabetes, semaglutide was associated with a lower five-year major cardiovascular event risk than other glp-1 receptor agonists.
What the study was
- Study design
- Target-trial emulation using an electronic-health-record cohort
- Population
- Obesity-related cancer survivors with type 2 diabetes
- Sample size
- 459
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes research and clinical practice
Why it surfaced
Score reflects the target-trial emulation using an electronic-health-record cohort design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.